CJC-1295 Side Effects in the Research Literature

Side effects reported in clinical literature

CJC-1295 side effects documented in the published record cluster into a small set. Teichman 2006 reported the compound as 'safe and relatively well tolerated' across the dose range studied, with the cleanest tolerability profile at 30-60 mcg/kg ^[1]. The trial enrolled healthy adults aged 21-61 and ran 28- and 49-day study windows; specific adverse events at higher doses (125 and 250 mcg/kg) included transient injection-site reactions ^[1].

The Van Hout and Hearne 2016 netnography of female CJC-1295 users in online community discussions documented self-reported events: injection-site redness, swelling, and itching; facial flushing; headache; dizziness; transient nausea; mild water retention ^[15]. These are observational, self-reported, and not from a controlled clinical trial — but they are the largest single inventory of community-reported events in the open literature.

The FDA Pharmacy Compounding Advisory Committee briefing in 2024 specifically referenced 'systemic vasodilatory reaction' as a safety concern for CJC-1295 in its review of non-approved peptide compounding ^[13]. The PCAC materials also flagged immunogenicity, impurities, and limited human clinical data as ongoing concerns for the substance class ^[13]. The compound was removed from Category 2 of the interim 503A bulks list in September 2024 following nominator withdrawal, pending further PCAC review ^[16].

Is CJC-1295 considered safe in the literature?

Short-term human exposure data is limited. Teichman 2006 — weeks of single-dose and multi-dose exposure in healthy adults — reported the compound as well tolerated at the doses studied, with the cleanest profile at 30-60 mcg/kg ^[1]. There is no published long-term human safety dataset. The compound has never received FDA approval for any indication ^[13][16]. The FDA's 2024 PCAC briefing identified immunogenicity, impurities, limited human data, and a noted systemic vasodilatory reaction profile as the principal safety concerns relevant to compounding ^[13]. WADA prohibits the substance under Section S2 of its Prohibited List, in-competition and out-of-competition ^[10].

Why CJC-1295 causes flushing

Histamine release and vasodilation following subcutaneous injection are the proposed mechanisms cited in pharmacy monographs and the FDA PCAC briefing ^[13]. The PCAC materials specifically reference 'systemic vasodilatory reaction' as a noted safety concern ^[13]. Facial flushing is one of the more frequently reported community events in the Van Hout 2016 netnography ^[15]. The reaction is typically transient — minutes to an hour post-injection — and is not consistently dose-related across the small published data.

Hair loss reports

Hair loss has not been documented as a side effect in published controlled trials of CJC-1295 ^[1]. The community-discussion record summarized by Van Hout 2016 contains scattered references to hair-related concerns, but these typically reference downstream IGF-1 elevation as a hypothesized mechanism rather than the peptide itself ^[15]. No quantitative incidence data exists in the peer-reviewed CJC-1295 literature.

Weight changes and water retention

Mild water retention is reported in the observational Van Hout 2016 netnography record ^[15]. The Teichman 2006 trial did not report significant weight change as a primary outcome — the study endpoints were pharmacokinetic (plasma GH, plasma IGF-1) rather than body-composition ^[1]. The closest body-composition signal in the broader GHRH-analog class comes from tesamorelin (a different molecule with FDA approval for HIV-associated lipodystrophy): 15-18% mean reduction in visceral adipose tissue versus placebo, with mild water retention reported as a class-typical effect ^[9].

Effect on testosterone

CJC-1295 acts on the GH/IGF-1 axis, not the hypothalamic-pituitary-gonadal (HPG) axis. Published trials measured GH and IGF-1 as primary endpoints; significant changes in testosterone have not been reported as a primary outcome ^[1]. The Sigalos 2017 paper documented elevated IGF-1 in hypogonadal men receiving combined GH-secretagogue and testosterone-replacement therapy — but the testosterone component came from exogenous administration in that protocol, not from CJC-1295 itself ^[11].

Discontinuation in clinical reports

GH and IGF-1 levels return toward baseline as the compound clears. The with-DAC variant's long half-life (~8 days) means residual activity persists for approximately one to two weeks after the last dose, with downstream IGF-1 normalization extending beyond pure peptide clearance ^[1]. The no-DAC variant clears within hours; pharmacodynamic GH effects are correspondingly short ^[6]. The DAC variant's long residence is one reason the FDA PCAC materials flagged acute discontinuation as a class concern: residual albumin-bound drug is not rapidly recoverable from plasma ^[13].

What are the side effects of CJC-1295?

Reported in published trials and case reports: injection-site reactions (redness, swelling, itching), facial flushing, headache, dizziness, transient nausea, and mild water retention ^[1][15]. The FDA PCAC 2024 briefing referenced cardiovascular concerns including systemic vasodilatory reaction ^[13]. Immunogenicity, impurities, and limited long-term human data are flagged as class concerns ^[13].

Does CJC-1295 cause hair loss?

Not documented as a side effect in published controlled trials of CJC-1295 ^[1]. Hair-related concerns in community discussion typically reference downstream IGF-1 elevation as a hypothesized mechanism rather than the peptide itself ^[15]. No quantitative incidence data exists in the peer-reviewed literature.

Does CJC-1295 cause weight gain?

Mild water retention is reported in observational sources ^[15]. Studied outcomes in published GH-axis research focus on body-composition shifts (lean-mass changes, adipose-tissue changes) rather than scale weight per se ^[9]. Teichman 2006 did not report scale weight as a primary endpoint ^[1].